493,276 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Bought by DDD Partners LLC

DDD Partners LLC purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 493,276 shares of the company’s stock, valued at approximately $5,974,000.

Several other institutional investors have also added to or reduced their stakes in ELAN. AM Squared Ltd bought a new stake in shares of Elanco Animal Health in the 3rd quarter valued at about $34,000. Wilmington Savings Fund Society FSB purchased a new position in Elanco Animal Health in the 3rd quarter worth approximately $35,000. Farther Finance Advisors LLC lifted its position in Elanco Animal Health by 158.7% in the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after purchasing an additional 2,044 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Elanco Animal Health by 89.9% during the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after purchasing an additional 1,601 shares during the period. Finally, Blue Trust Inc. grew its holdings in shares of Elanco Animal Health by 2,129.2% in the third quarter. Blue Trust Inc. now owns 3,968 shares of the company’s stock worth $57,000 after purchasing an additional 3,790 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Down 3.4 %

Shares of NYSE:ELAN opened at $11.26 on Monday. The firm has a market capitalization of $5.57 billion, a P/E ratio of 28.15, a P/E/G ratio of 2.69 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock has a 50 day moving average price of $11.94 and a 200-day moving average price of $13.15. Elanco Animal Health Incorporated has a 52-week low of $10.77 and a 52-week high of $18.80.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ELAN. Barclays increased their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Morgan Stanley dropped their target price on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a report on Wednesday, January 29th. UBS Group initiated coverage on Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 price target on the stock. Stifel Nicolaus dropped their price objective on Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $16.29.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.